GlassScriptPhysician profile
Edward A Stadler
NPI 1699723932
$1,777.63
in general payments reported to CMS, 2019-2025
25 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $61.46 · 2021: $11.27 · 2022: $440 · 2023: $417 · 2024: $218 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $786.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $263.08 | 2019-2023 | Lo Loestrin Fe |
| Astellas Pharma US INC | $211.40 | 2019-2025 | Veozah |
| Biogen, INC. | $137.90 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $136.86 | 2019-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $123.91 | 2019-2024 | |
| Daiichi Sankyo INC. | $120.62 | 2019-2022 | |
| Hologic Sales and Service, LLC | $111.74 | 2019-2023 | Aptima |
| Mayne Pharma Commercial LLC | $84.01 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $71.30 | 2023 | Myrisk |
| Shield Therapeutics INC | $68.93 | 2022-2023 | Accrufer |
| Organon LLC | $59.25 | 2022-2023 | Nexplanon |
| Pfizer INC. | $46.86 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $44.80 | 2019 | |
| Myriad Women'S Health, INC. | $44.17 | 2023 | Myrisk |
| Sumitomo Pharma America, INC. | $40.97 | 2023 | Myfembree |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $33.85 | 2025 | Cologuard Collection Kit |
| Coopersurgical, INC. | $28.84 | 2019-2025 | Paragard T 380a |
| Evofem Biosciences, INC. | $28.57 | 2022 | |
| Avion Pharmaceuticals | $24.70 | 2019-2021 | |
| Aspira Women'S Health INC | $18.63 | 2022 | |
| Horizon Therapeutics Plc | $17.98 | 2019 | |
| Amag Pharmaceuticals, INC. | $17.74 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $17.24 | 2023 | Vivjoa |
| Covidien LP | $12.90 | 2019 | |
| Therapeuticsmd, INC. | $11.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Stadler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.